Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 13/20 | 0.47 |
| ▸ | MTOR | P42345 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 12/20 | 0.42 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.42 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.37 |
| ▸ | RAF1 | P04049 | 2/20 | 0.37 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.37 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.37 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5201273 | 0.88 | TGFBR1 (0.47) | TGFBR1MTORKDM4EMAPK14RIPK2 | |
| SCHEMBL5199866 | 0.88 | TGFBR1 (0.48) | TGFBR1MTORKDM4EMAPK14RIPK2 | |
| SCHEMBL5199459 | 0.86 | TGFBR1 (0.49) | TGFBR1MTORKDM4EMAPK14RIPK2 | |
| SCHEMBL5199902 | 0.86 | TGFBR1 (0.46) | TGFBR1MTORKDM4EMAPK14RIPK2 | |
| SCHEMBL5199441 | 0.85 | TGFBR1 (0.47) | TGFBR1MTORKDM4EMAPK14RIPK2 | |
| SCHEMBL5197675 | 0.84 | TGFBR1 (0.46) | TGFBR1MTORKDM4EMAPK14RIPK2 | |
| SCHEMBL5198045 | 0.84 | KDM4E (0.47) | TGFBR1MTORKDM4EMAPK14RIPK2 | |
| SCHEMBL5197454 | 0.84 | TGFBR1 (0.44) | TGFBR1MTORKDM4EMAPK14RIPK2 | |
| SCHEMBL5199363 | 0.83 | TGFBR1 (0.45) | TGFBR1MTORKDM4EMAPK14RIPK2 | |
| SCHEMBL5200006 | 0.83 | TGFBR1 (0.45) | TGFBR1MTORKDM4EMAPK14RIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275968-A1 | Substituted Biphenyl Derivative | SANKYO COMPANY, LIMITED (JP) | 2007-11-29 | — | — | US | disclosed |
| EP-1798229-A1 | SUBSTITUTED BIPHENYL DERIVATIVE | Sankyo Company, Limited (JP) | 2007-06-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275968-A1 | Substituted Biphenyl Derivative | COL2A1, COL1A1, FGFR3 | TGFBR1 40/4885MTOR 3462/4885KDM4E 806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.